{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:10:44Z","timestamp":1793815844508,"version":"4.6.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ctrv.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:35:53Z","timestamp":1529350553000},"page":"177-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":291,"special_numbering":"C","title":["Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases"],"prefix":"10.1016","volume":"69","author":[{"given":"Sven","family":"Otto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Pautke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schi\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.06.007_b0005","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.06.007_b0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0015","unstructured":"von Moos R, Henry D, Body JJ, Rider A, De Courcy J, Murray G, et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer treated in real-world practice. In: 18th ECCO \u2013 40th ESMO European cancer congress, Vienna, Austria 25\u201329 September 2015. p. 294."},{"key":"10.1016\/j.ctrv.2018.06.007_b0020","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12452","article-title":"Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study","volume":"26","author":"Duran","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ctrv.2018.06.007_b0025","first-page":"8","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ctrv.2018.06.007_b0030","unstructured":"Zometa [summary of product characteristics]. Camberley (UK): Novartis Europharm Ltd; 2018."},{"key":"10.1016\/j.ctrv.2018.06.007_b0035","unstructured":"Xgeva [summary of product characteristics]. Breda (The Netherlands): Amgen B. V.; 2018."},{"key":"10.1016\/j.ctrv.2018.06.007_b0040","unstructured":"Aclasta [summary of product characteristics]. Camberley (UK): Novartis Europharm Ltd; 2018."},{"key":"10.1016\/j.ctrv.2018.06.007_b0045","unstructured":"Prolia [summary of product characteristics]. Breda (The Netherlands): Amgen B. V.; 2018."},{"key":"10.1016\/j.ctrv.2018.06.007_b0050","unstructured":"Xgeva [prescribing information]. Thousand Oaks (USA): Amgen Inc.; 2018."},{"key":"10.1016\/j.ctrv.2018.06.007_b0055","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2018.06.007_b0060","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0065","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00520-015-2908-1","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0070","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw \u2013 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0075","first-page":"53","article-title":"Bisphosphonate \u2013 related osteonecrosis of the jaws: the point of view of the oral pathologist","volume":"4","author":"Ficarra","year":"2007","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.ctrv.2018.06.007_b0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jcms.2010.05.009","article-title":"Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence: a multi-centre study","volume":"39","author":"Otto","year":"2011","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0085","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2018.06.007_b0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2018.06.007_b0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0100","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2018.06.007_b0110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1159\/000343950","article-title":"Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation","volume":"35","author":"Then","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.ctrv.2018.06.007_b0115","unstructured":"Fleisher KE, Kontio R, Otto S. Antiresorptive drug-related osteonecrosis of the jaw (ARONJ) \u2013 a guide to research. Davos Platz (Switzerland): AO Foundation; 2016. Available at: <http:\/\/www.maaszt.hu\/images\/pdf\/ARONJ2016.pdf> [last accessed 11 June 2018]."},{"key":"10.1016\/j.ctrv.2018.06.007_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws \u2013 characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bdj.2017.79","article-title":"Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners","volume":"222","author":"Tanna","year":"2017","journal-title":"Br Dent J"},{"key":"10.1016\/j.ctrv.2018.06.007_b0130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2018.06.007_b0140","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ejca.2015.07.025","article-title":"Age and case mix-standardised survival for all cancer patients in Europe 1999\u20132007: results of EUROCARE-5, a population-based study","volume":"51","author":"Baili","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0150","doi-asserted-by":"crossref","first-page":"427273","DOI":"10.1155\/2014\/427273","article-title":"Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients","volume":"2014","author":"Melea","year":"2014","journal-title":"Int J Dent"},{"key":"10.1016\/j.ctrv.2018.06.007_b0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdn630","article-title":"Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome","volume":"20","author":"Van den Wyngaert","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2013a review","volume":"48","author":"Kuhl","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0165","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hed.20864","article-title":"Treatment results of bisphosphonate-related osteonecrosis of the jaws","volume":"30","author":"Wutzl","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2018.06.007_b0170","unstructured":"Baniasadi B, Coropciuc R, Dormaar JT, Grysolle A, Gustin Th, Javadian R, et al. Consensus document on the management of osteonecrosis of the jaw (ONJ) from Belgium; 2014. Unpublished results\/personal communication."},{"key":"10.1016\/j.ctrv.2018.06.007_b0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","article-title":"Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed","volume":"53","author":"Fedele","year":"2015","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","article-title":"Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system","volume":"117","author":"Schiodt","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0185","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.06.007_b0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0195","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00520-016-3492-8","article-title":"Response to letter to the Editors: safety of long-term denosumab therapy","volume":"25","author":"Stopeck","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0200","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jcms.2016.09.018","article-title":"Clinical features of peri-implant medication-related osteonecrosis of the jaw: is there an association to peri-implantitis?","volume":"44","author":"Troeltzsch","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.oooo.2014.12.024","article-title":"Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort","volume":"119","author":"Yazdi","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.oooo.2015.08.007","article-title":"Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review","volume":"120","author":"Nicolatou-Galitis","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0220","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.coms.2015.06.005","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"27","author":"Fung","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2018.06.007_b0225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2018.06.007_b0230","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.joms.2013.11.005","article-title":"Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?","volume":"72","author":"Ristow","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0235","doi-asserted-by":"crossref","first-page":"36129","DOI":"10.1038\/srep36129","article-title":"Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2018.06.007_b0240","first-page":"58","article-title":"Prevention of bisphosphonates-induced osteonecrosis","volume":"4","author":"Baraldi","year":"2007","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.ctrv.2018.06.007_b0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0250","series-title":"Medication-related osteonecrosis of the jaws","author":"Otto","year":"2015"},{"key":"10.1016\/j.ctrv.2018.06.007_b0255","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coms.2015.06.004","article-title":"The role of antiangiogenic therapy in the development of osteonecrosis of the jaw","volume":"27","author":"Fantasia","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2018.06.007_b0260","doi-asserted-by":"crossref","first-page":"829P","DOI":"10.1093\/annonc\/mdw373.56","article-title":"Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude Des Tumeurs Uro Genitales)","volume":"27","author":"Guillot","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0265","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2018.06.007_b0270","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.06.007_b0280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.06.007_b0285","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S2213-8587(17)30178-X","article-title":"Safety of long-term denosumab therapy for osteoporosis","volume":"5","author":"Compston","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0290","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0295","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2018.06.007_b0300","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0305","unstructured":"Body JJ, Von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F, et al. Real-world use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in real-world practice in the European Union. In: 18th ECCO \u2013 40th ESMO European Cancer Congress, Vienna, Austria 25\u201329 September 2015. p. 298."},{"key":"10.1016\/j.ctrv.2018.06.007_b0310","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00520-013-1934-0","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"Van den Wyngaert","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ctrv.2018.06.007_b0320","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","article-title":"Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid \u2013 a prospective study over 6 years","volume":"44","author":"Mucke","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0330","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer","volume":"100","author":"Sim Ie","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2018.06.007_b0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00520-014-2309-x","article-title":"Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom","volume":"23","author":"Hechmati","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0340","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4999\/uhod.15838","article-title":"Patients' preferences for bone metastases treatments in Turkey","volume":"25","author":"Gatta","year":"2015","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0345","unstructured":"Oncology Pocket Guide to Oral Health. National Institutes of Health: National Institute of Dental and Craniofacial Research. Last reviewed on September 2017. Available at: <https:\/\/www.nidcr.nih.gov\/oncology-pocket-guide-oral-health> [last accessed: 11 June 2018]."},{"key":"10.1016\/j.ctrv.2018.06.007_b0350","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1345\/aph.1M102","article-title":"Denosumab in osteoporosis and oncology","volume":"43","author":"Burkiewicz","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ctrv.2018.06.007_b0355","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2018.06.007_b0360","doi-asserted-by":"crossref","first-page":"1801676","DOI":"10.1155\/2016\/1801676","article-title":"Medication-related osteonecrosis of the jaws: considerations on a new antiresorptive therapy (denosumab) and treatment outcome after a 13-year experience","volume":"2016","author":"Favia","year":"2016","journal-title":"Int J Dent"},{"key":"10.1016\/j.ctrv.2018.06.007_b0365","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0022034515572021","article-title":"Infection and medication-related osteonecrosis of the jaw","volume":"94","author":"Katsarelis","year":"2015","journal-title":"J Dent Res"},{"key":"10.1016\/j.ctrv.2018.06.007_b0370","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.oooo.2012.08.442","article-title":"Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw","volume":"117","author":"Heufelder","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0375","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.2525","article-title":"Comments on \u201cdiagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus\u201d","volume":"30","author":"Otto","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2018.06.007_b0380","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jcms.2016.05.018","article-title":"Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: a prospective cohort study","volume":"44","author":"Otto","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0385","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","article-title":"Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)","volume":"43","author":"Ristow","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0390","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tripleo.2011.02.037","article-title":"Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center","volume":"112","author":"Nicolatou-Galitis","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.ctrv.2018.06.007_b0395","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejon.2011.02.006","article-title":"Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers","volume":"16","author":"Jensen","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.ctrv.2018.06.007_b0400","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-centre study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0405","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0410","unstructured":"Schiodt M, Otesen C, Dalsten H, Oturay P, Kofod T. Surgical treatment outcome of 141 consecutive patients with medication-related osteonecrosis of the jaws (MRONJ) from the Copenhagen ONJ cohort, 13\u201316 September 2016. London (UK): European Association for Cranio Maxillo-Facial Surgery (EACMFS). p. Oral Presentation Session 4."},{"key":"10.1016\/j.ctrv.2018.06.007_b0415","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","article-title":"A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)","volume":"50","author":"Rupel","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0420","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0425","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00784-013-0979-2","article-title":"Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study","volume":"18","author":"Lesclous","year":"2014","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.ctrv.2018.06.007_b0430","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","article-title":"A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer","volume":"26","author":"Schiodt","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0435","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcms.2013.05.038","article-title":"Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection","volume":"41","author":"Otto","year":"2013","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0440","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bjoms.2010.08.005","article-title":"Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw","volume":"49","author":"McLeod","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0445","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/pho.2015.3927","article-title":"Medication-related osteonecrosis of the jaw: an autofluorescence-guided surgical approach performed with Er:YAG laser","volume":"33","author":"Vescovi","year":"2015","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0450","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.joms.2015.01.008","article-title":"Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution","volume":"73","author":"Lopes","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0455","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bjoms.2016.06.015","article-title":"Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: a series of 120 patients","volume":"54","author":"Nisi","year":"2016","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0460","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0465","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","article-title":"Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates","volume":"25","author":"Lasseter","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2018.06.007_b0470","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.ctrv.2018.06.007_b0475","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.joms.2009.07.079","article-title":"Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?","volume":"68","author":"Otto","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0480","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","article-title":"Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism","volume":"68","author":"Otto","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2018.06.007_b0485","doi-asserted-by":"crossref","first-page":"864","DOI":"10.14219\/jada.archive.2009.0280","article-title":"Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review","volume":"140","author":"Almazrooa","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.ctrv.2018.06.007_b0490","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00432-014-1588-4","article-title":"Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?","volume":"140","author":"Ristow","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0495","unstructured":"Drug Safety Update \u2013 Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal. Medicines and Healthcare products Regulatory Agency. Last updated 14 December 2015. Available at: <https:\/\/www.gov.uk\/drug-safety-update\/bisphosphonates-very-rare-reports-of-osteonecrosis-of-the-external-auditory-canal> [last accessed 11 June 2018]."},{"key":"10.1016\/j.ctrv.2018.06.007_b0500","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00405-011-1496-z","article-title":"Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study","volume":"268","author":"Froelich","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.ctrv.2018.06.007_b0505","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/1097-0142(19921015)70:8<2171::AID-CNCR2820700827>3.0.CO;2-S","article-title":"Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy","volume":"70","author":"Jansma","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2018.06.007_b0510","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7257\/1053-816X.2016.36.3.117","article-title":"Retrospective audit: does prior assessment by oral and maxillofacial surgeons reduce the risk of osteonecrosis of the jaw in patients receiving bone-targeted therapies for metastatic cancers to the skeleton? Part II","volume":"36","author":"Turner","year":"2016","journal-title":"Urol Nurs"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218301014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218301014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T12:29:26Z","timestamp":1571488166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218301014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":102,"alternative-id":["S0305737218301014"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}